<DOC>
	<DOCNO>NCT01357772</DOCNO>
	<brief_summary>The long-lasting phase precursor invasive cancer , i.e . dysplasia intraepithelial neoplasia ( IEN ) , particularly relevant among risk determinant . At present , 15-20 % breast cancer diagnose non-invasive phase . Despite good prognosis , woman breast IEN ( lobular ductal intraepithelial neoplasia , LIN DIN ) 10-15/1000 annual risk invasive disease ( 8-10 time age general population ) , thus represent important target chemoprevention . In National Surgical Adjuvant Breast Bowel Project ( NSABP-P1 trial ) , tamoxifen use 20 mg/day associate 86 % reduction invasive breast cancer woman previous atypical ductal hyperplasia ( ADH ) ( RR=0.14 , 95 % IC , 0.03-0.47 ) 56 % risk reduction woman previous Lobular Carcinoma situ ( LCIS ) ( RR=0.44 , 95 % IC , 0.16-1.06 ) . However , tamoxifen use set hamper serious adverse event attributable partial estrogenic activity , increase risk endometrial cancer venous thromboembolism , significantly limit broad use chemoprevention . To improve risk-benefit ratio , use low dos drug propose . Recent trial group show dose reduce 1 mg/day loss tamoxifen antiproliferative activity breast cancer . By contrast , dose 5 mg/day increase endometrial proliferation associate decrease estrogenic activity tamoxifen insulin like growth factor ( IGF-I ) , sex hormone-binding globulin ( SHBG ) antithrombin-III , potential decrease venous thromboembolic event . Moreover , tamoxifen exhibit high tissue distribution , dose 5 mg/day attains breast tissue level concentration 10 time higher needed inhibit cell growth vitro . The promising clinical activity 5 mg/day tamoxifen support ongoing 2x2 phase IIb trial low-dose tamoxifen fenretinide premenopausal woman , tamoxifen lower breast cancer event compare placebo . The cytochromeP450 2D6 ( CYP2D6 ) enzyme mediates oxidation N-desmethyl tamoxifen endoxifen , active metabolite tamoxifen . The single nucleotide polymorphism ( SNP ) CYP2D6*4 ( 1846G &gt; A ) allele account 75 % CYP2D6 poor metabolizer phenotype poor metabolizers show trend high risk develop breast event compare wildtype .</brief_summary>
	<brief_title>Trial Low Dose Tamoxifen Women With Breast Intraepithelial Neoplasia</brief_title>
	<detailed_description>The time interval Study Start Date ( November 2008 ) Study First Release ( May 17 , 2011 ) relate bureaucratic problem .</detailed_description>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Women age &lt; 75 year Women operate lobular ( LIN 2 3 ) ER positive unknown ductal ( DIN 13 , exclude DIN 1a ) intraepithelial neoplasia . Both incident ( diagnosis within 12 month ) prevalent case ( diagnosis previous 12 60 month ) include , upon stratification . Written informed consent Any type malignancy , exclusion nonmelanoma skin cancer ; Active proliferative disorder endometrium atypical hyperplasia , history active endometriosis , unresected polyp ; Alterations metabolic , liver , renal cardiac grade 2 function ( NCI criterion grade 2 high ) ; Any type retinal disorder severe cataract ; Presence significant risk factor venous event , include immobilization within last 3 month longer 2 week follow surgery trauma , deep venous thrombophlebitis significant venous thrombotic event ( VTE ) ( pulmonary embolism , stroke , etc . ) ; Use tamoxifen , raloxifene selective estrogen receptor modulator ( SERMs ) within last 4 week ; Anticoagulant therapy progress ( heparin dicoumarol ) ; Active infection ; Severe psychiatric disorder inability comply protocol procedure .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>